Press coverage about Halozyme Therapeutics (NASDAQ:HALO) has trended somewhat positive this week, Accern reports. The research group identifies positive and negative news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Halozyme Therapeutics earned a media sentiment score of 0.12 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 46.5513732523315 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

These are some of the news stories that may have effected Accern Sentiment Analysis’s scoring:

Shares of Halozyme Therapeutics (NASDAQ HALO) traded up $0.50 during mid-day trading on Tuesday, hitting $19.20. The company had a trading volume of 1,802,584 shares, compared to its average volume of 1,416,965. The company has a debt-to-equity ratio of 2.01, a current ratio of 3.46 and a quick ratio of 3.37. Halozyme Therapeutics has a fifty-two week low of $9.68 and a fifty-two week high of $19.37.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.06 by ($0.04). The company had revenue of $63.73 million during the quarter, compared to the consensus estimate of $58.95 million. Halozyme Therapeutics had a negative net margin of 53.17% and a negative return on equity of 892.57%. The company’s quarterly revenue was up 100.1% on a year-over-year basis. During the same quarter last year, the firm posted ($0.23) earnings per share. analysts predict that Halozyme Therapeutics will post 0.15 earnings per share for the current year.

HALO has been the subject of a number of research analyst reports. Zacks Investment Research cut Halozyme Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, August 24th. Deutsche Bank AG boosted their price objective on Halozyme Therapeutics to $20.00 and gave the stock a “buy” rating in a report on Friday, September 15th. Canaccord Genuity boosted their price objective on Halozyme Therapeutics from $17.00 to $19.00 and gave the stock a “buy” rating in a report on Wednesday, November 8th. BMO Capital Markets boosted their price objective on Halozyme Therapeutics from $14.00 to $15.00 and gave the stock a “market perform” rating in a report on Friday, September 15th. Finally, Piper Jaffray Companies set a $20.00 price objective on Halozyme Therapeutics and gave the stock a “buy” rating in a report on Thursday, August 10th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and four have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $17.75.

TRADEMARK VIOLATION NOTICE: This article was first published by Watch List News and is owned by of Watch List News. If you are reading this article on another website, it was stolen and reposted in violation of United States & international copyright legislation. The correct version of this article can be read at https://www.watchlistnews.com/halozyme-therapeutics-halo-receives-media-sentiment-rating-of-0-12/1718518.html.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.

Insider Buying and Selling by Quarter for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.